Debate: The slippery slope of surrogate outcomes

AUTOR(ES)

D'Agostino, Ralph B

FONTE

BioMed Central

RESUMO

Surrogate outcomes are frequently used in cardiovascular disease research. A concern is that changes in surrogate markers may not reflect changes in disease outcomes. Two recent clinical trials (Heart and Estrogen/Progestin Replacement Study [HERS], and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]) underscore this problem since their results contradicted what was expected based on the surrogate outcomes. The current regulatory policy to allow new therapies to be introduced onto the market based solely on surrogate outcomes may need to be reviewed.

Documentos Relacionados

• Debate: Are surrogate end-point studies worth the effort?
• Euthanasia in The Netherlands--down the slippery slope?
• Humanitarian medicine: up the garden path and down the slippery slope
• Physician assisted deaths: no “slippery slope” in the Netherlands or Oregon
• Industry funded patient information and the slippery slope to New Zealand